675 related articles for article (PubMed ID: 31014177)
1. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
3. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
4. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
5. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
7. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Haq N; Chaaban A; Gebran N; Khan I; Abbachi F; Hassan M; Bernsen R; Abouchacra S
Int Urol Nephrol; 2014 Jan; 46(1):113-9. PubMed ID: 23529273
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
11. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism.
Eddington H; Chinnadurai R; Alderson H; Ibrahim ST; Chrysochou C; Green D; Erekosima I; Hutchison A; Bubtana A; Hegarty J; Kalra PA
BMC Nephrol; 2021 Mar; 22(1):106. PubMed ID: 33757437
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Mercadal Orfila G; Blasco Mascaró I
Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
[TBL] [Abstract][Full Text] [Related]
17. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
18. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H
Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
